Dr. Zengjun Li 李增军
Chief Physician
Department of Lymphoma, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive diagnosis and treatment of lymphatic system tumors, including chemotherapy and hematopoietic stem cell transplantation for lymphoma, multiple myeloma, and acute or chronic lymphocytic leukemia.
Dr. Li holds a PhD in Hematology and has nearly 20 years of experience in hematology. Current work focuses on clinical care and research for lymphatic tumors. Dr. Li has published over 100 articles, co-edited 10 books, and participated in over 20 multicenter clinical trials, serving as principal investigator for 8.
Professional roles
- Member, Anti-Lymphoma Alliance, Chinese Society of Clinical Oncology (CSCO)
- Member, Hematopathology Working Group and Chronic Lymphocytic Leukemia Working Group, Blood Tumor Committee, China Anti-Cancer Association
- Member and Secretary, Blood Tumor Committee, Tianjin Anti-Cancer Association
- Member, Hematology Branch, Tianjin Medical Doctor Association
Name order: in Chinese the family name comes first (Li Zengjun). Papers usually list the name as Zengjun Li or Li Z.
Selected publications
57 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Haematologica, 2026 (senior author): Comprehensive evaluation of safety and efficacy: TEAM versus BEAM as conditioning for autologous transplantation in patients with lymphoma. PubMed 42489071
- J Gastrointest Cancer, 2026 (senior author): Radiofrequency Ablation in the Treatment of Chronic Radiation Enteritis. PubMed 42018054
- Front Oncol, 2026 (senior author): Research progress on resistance mechanisms to CAR-T cell therapy in diffuse large B-cell lymphoma. PubMed 41800035
- Front Immunol, 2025 (senior author): Case Report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma. PubMed 41235228
- Front Oncol, 2025 (senior author): Case Report: Transformation of natural killer-cell large granular lymphocytic leukemia to aggressive natural killer cell leukemia. PubMed 40951347
- Cancer, 2025 (senior author): Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study. PubMed 39748728
- Front Oncol, 2024 (senior author): Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma. PubMed 39834945
- Front Oncol, 2022 (senior author): Case report: Successful management of a refractory double-expressor diffuse large B-cell lymphoma patient under the guidance of in vitro high-throughput drug sensitivity test. PubMed 36741708
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion